Literature DB >> 6198447

Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.

M Ferguson, P D Minor, D I Magrath, Y H Qui, M Spitz, G C Schild.   

Abstract

Monoclonal antibodies to poliovirus type 3 secreted by 51 hybridoma cell clones have been characterized in terms of (i) virus-neutralizing properties, (ii) reactivity in antigen-blocking tests with infectious, 155S ('D' antigen) and empty 80S ('C' antigen) poliovirus particles and (iii) reactivity in immunoblot tests with the isolated protein components of the poliovirus capsid. The antibodies could be separated into three groups on the basis of their reactivities with 'D' and 'C' antigens. All antibodies that reacted with both 'D' and 'C' antigen had potent neutralizing activity. Only a proportion of antibodies that reacted uniquely with 'D' antigen possessed neutralizing activity. Unexpectedly, one of 24 'C' antigen-specific antibodies inhibited virus growth. None of the antibodies that possessed virus-neutralizing activity reacted with isolated poliovirus capsid proteins, although the majority of these have been shown in previous studies to be specific for VP1 on intact virus particles. These findings suggest that antigenic determinants involved in virus neutralization do not survive the denaturing conditions required for the isolation of poliovirus capsid proteins and consequently are likely to be specified by the structural conformation of VP1 rather than by amino acid sequence alone. However, several of the antibodies which bound uniquely to 'C' antigen reacted in immunoblot tests, five with VP1 and one with VP3. Some of these antibodies also possessed heterotypic reactivity with the corresponding capsid proteins separated from other poliovirus types.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198447     DOI: 10.1099/0022-1317-65-1-197

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.

Authors:  B Blondel; R Crainic; O Fichot; G Dufraisse; A Candrea; D Diamond; M Girard; F Horaud
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

2.  Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells.

Authors:  M J Grubman; D O Morgan; J Kendall; B Baxt
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

3.  Neutralizing activity of monoclonal antibodies to heat-sensitive and heat-resistant epitopes of Rickettsia rickettsii surface proteins.

Authors:  R L Anacker; G A McDonald; R H List; R E Mann
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

4.  Antigenic modification of polioviruses by host proteolytic enzymes.

Authors:  M Roivainen; A Huovilainen; T Hovi
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

5.  Evaluation of a poliovirus-binding inhibition assay as an alternative to the virus neutralization test.

Authors:  M M Herremans; J H Reimerink; A Ras; H G Van Der Avoort; T G Kimman; A M Van Loon; M A Conyn-Van Spaendonck; M P Koopmans
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

6.  Three-dimensional model of the capsid proteins of two biologically different Theiler virus strains: clustering of amino acid difference identifies possible locations of immunogenic sites on the virion.

Authors:  D C Pevear; M Luo; H L Lipton
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

7.  Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.

Authors:  Xiaoli Wang; Zhiqiang Ku; Xiang Zhang; Xiaohua Ye; Jinhuan Chen; Qingwei Liu; Wei Zhang; Chao Zhang; Zhenglin Fu; Xia Jin; Yao Cong; Zhong Huang
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

8.  An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16.

Authors:  O Jenkins; J Cason; K L Burke; D Lunney; A Gillen; D Patel; D J McCance; J W Almond
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

9.  Analysis of neutralizing epitopes on foot-and-mouth disease virus.

Authors:  E Pfaff; H J Thiel; E Beck; K Strohmaier; H Schaller
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.